$TWST

Twist Bioscience Corp

Twist Bioscience develops and manufactures synthetic DNA and related products using a platform that writes DNA on silicon chips. Its customers include life sciences researchers, biotechnology and pharmaceutical companies, diagnostic companies, hospitals, research institutions, agricultural biotechnology companies, industrial chemical companies and academic labs. Twist’s products include synthetic biology tools such as genes, gene fragments, oligonucleotide pools, RNA and proteins; next-generation sequencing tools, including library preparation kits and target enrichment panels; and synthetic controls. It also provides biopharma services for antibody discovery, optimization and development, including screening, assays, antibody expression and characterization. Twist makes money by selling products and services, and earns licensing and service fees from antibody partnerships, which may also include success-based milestones and royalties. It sells worldwide through direct sales, consultants, e-commerce and distributors. Twist is headquartered in South San Francisco, California.

14
3
14
—
$1.6M
Green Paula
0%
See all $TWST insider activity →

ARK Invest Adds $16.2 Million in NVIDIA and $16 Million in CoreWeave

ARK Invest added $16.2M to NVIDIA (NVDA) and $16M to CoreWeave (CRWV), while reducing positions in Tempus AI (TEM) and Palantir (PLTR) by $12.8M and $11.8M, respectively. Other buys included ACHR, TWST, PRME, and SOFI. Sells included AMZN, TER, SNPS, AVGO, XYZ, and BYDDY.

TWST sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 31 news stories mentioning TWST (Twist Bioscience Corp). Coverage has been balanced: 14 bullish, 3 neutral, and 14 bearish.

Recent TWST coverage spans financial news, earnings and insider activity.

In the last 30 days, TWST insiders filed 7 SEC Form 4 transactions — no purchases and 7 sales ($1.6M). The most active reporter was Green Paula, SVP of Human Resources, with 2 filings.

What's driving TWST

AlphAI scores every news story that mentions TWST with an AI model for sentiment and relevance, and aggregates insider trades from Twist Bioscience Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $TWST

Score

Cathie Wood Boosts Bets On 2 AI Firms Amid Nvidia’s Huang Upheaval — Here’s How Her Trading Week Unfolded

ARK Investment Management, led by Cathie Wood, disclosed $75.53M in stock purchases this week, including $16.16M in Nvidia (NVDA) and $16.02M in CoreWeave (CRWV). ARK also added to Archer Aviation (ACHR) and Rocket Lab (RKLB), while selling BYD (BYDDY) shares. CoreWeave reported $3.66B in revenue and a $132.5B backlog. Wood remains optimistic about AI and EV adoption.

Twist Bioscience Corporation Q4 2026 Earnings Call Summary

Twist Bioscience reported positive adjusted EBITDA in Q4 2026, with revenue growth driven by a 175% YoY increase in AI drug discovery. The company expects $550M-$560M revenue in 2027, with $100M from AI drug discovery. It plans $150M in CapEx over two years to support future growth. Management highlighted structural advantages and strategic initiatives in AI and nucleic acid therapeutics.

Full-Year Revenue Guidance and Strong Quarter Drove Twist Bioscience Corporation (TWST) Higher in Q3

Artisan Partners' Q3 2026 investor letter highlights Twist Bioscience (TWST) as a top performer, citing strong revenue growth and raised full-year guidance. The biotech company specializes in synthetic DNA products, with shares up 310% over the past year despite a recent pullback. Artisan notes AI-driven demand and management's EBITDA breakeven target as key growth drivers.

$TWSTHighAI 8/10Earnings

Twist Bioscience Reports Fiscal Fourth Quarter and Full Year Fiscal 2026 Financial Results

Twist Bioscience Corp (TWST) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Twist Bioscience Reports Fiscal Fourth Quarter and Full Year Fiscal 2026 Financial Results — Record revenue of $459.4 million in Fiscal 2026; Increase of 22% over $376.6 million in Fiscal 2025 — — Record revenue of $126.6 million in 4QFY26 ; Increase of approximately

Related tickers